NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq: SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today reported financial results for the quarter and nine months ended September 30, 2008. Revenues for the quarter increased 5% to $6.9 million, compared to $6.6 million for the same period in 2007. Revenues for the third quarter of 2008 were positively impacted by a 38% year-over-year increase in sales of Food Pathogen products, a 14% year-over-year increase in sales of Water and Environmental products, and a 191% year-over-year increase in sales of Genomic Antibody Technology™ (GAT™) products. These solid gains were offset by a decline of 8% in Antibody revenues. As previously announced, the antibody business was adversely affected by decreased orders of Bulk and Monoclonal antibodies by customers who had accumulated excess inventories.
